Genmab — Juli 2020
-
Pharma retter sig nu. Vi mangler bare at Genmab følger med.
-
Mon det er manden “in house“ der kan efterfølge JW ? https://www.linkedin.com/posts/anthony-mancini-4b50b61_genmabnews-activity-6692094001799151616-TELR ved godt Helge har opslået den tidligere, men hans ordvalg ligner en der tegner firmaet.
-
Også min tanke Solsen.

-
-
Jeg tror alle tager det roligt med Genmab og anden god pharma/biotek. Uro ses som regel hos dem med gearede positioner.
-
Jan går ikke på pension før Genmab er blevet et ikonisk biotekselskab

-
a bit surprised that this Nivolumab/ Daratumumab trial in Lung / Breast cancer is extending Study Completion date by a year. Makes me wonder how many they actually recruited and still have benefit https://clinicaltrials.gov/ct2/history/NCT03098550?A=29&B=30&C=merged#StudyPageTop
-
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Blenrep (belantamab mafodotin) to treat adult patients with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, a proteasome inhibitor and a CD-38 monoclonal antibody. https://www.ema.europa.eu/en/news/first-antibody-drug-conjugate-multiple-myeloma-patients-limited-treatment-options
-
Det strømmer ikke ligefrem med større købere på nogen niveauer i dag.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind